Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (LGVN) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026.
The company’s presentation is scheduled for Monday, September 14, 2026, from 1:00–1:30 p.m. ET. A webcast of the presentation will be available via the “Events and Presentations” section of Longeveron’s website.
Longeveron (NASDAQ: LGVN) will implement a 1‑for‑10 reverse stock split of its Class A and Class B common stock, effective 11:59 p.m. ET on August 26, 2026. Split‑adjusted Class A shares will begin trading on August 27, 2026 under ticker LGVN and new CUSIP 54303L 302.
The reverse split, previously approved by stockholders and the board, is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price. Outstanding Class A shares will decline from about 30.43 million to 3.04 million, and Class B from about 1.45 million to 144,901, with no change to authorized shares or par value. Fractional shares will be rounded up at the DTC participant level, and related warrants and equity awards will be proportionally adjusted.
Longeveron (NASDAQ: LGVN) appointed Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, joining the executive leadership team and succeeding Marie Washburn, who returns to her prior role as Corporate Controller.
According to Longeveron, Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector and prior CFO roles at Opus Genetics (Nasdaq: IRD), Insilico Medicine (HKEX: 3696.HK) and Journey Medical (Nasdaq: DERM). The company also highlighted ongoing development of its stem cell therapy laromestrocel, with top-line data from a Phase 2b trial in HLHS expected in September 2026.
Longeveron (NASDAQ: LGVN) reported 2026 second quarter revenue of $0.3 million, down 10% year over year, with gross profit of $0.2 million, up 25%. Net loss widened to $6.1 million from $5.0 million, driven by higher legal and clinical trial expenses. Cash and cash equivalents were $10.1 million at June 30, 2026, which the company expects will fund operations into the fourth quarter of 2026.
Top-line results from the Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome are anticipated in September 2026, following a Data Monitoring Committee review indicating no safety concerns. Longeveron was selected as a Finalist Team in the XPRIZE Healthspan competition and will receive a $1.0 million Milestone 2 award. Additional updates covered Alzheimer’s disease, aging-related frailty, pediatric dilated cardiomyopathy, patent grants, EMA SME status, and new independent directors.
Longeveron (NASDAQ: LGVN) has been selected from over 600 global applicants as a Milestone 2 Awardee and Finalist Team in the XPRIZE Healthspan competition. The company will receive a $1,000,000 Milestone 2 Award to fund its competition clinical trial of laromestrocel, an allogeneic mesenchymal stem cell therapy.
Longeveron’s selection was based on published clinical trial results in Aging-related Frailty showing increased 6-minute walk distance. Laromestrocel has shown positive initial data across 5 trials in 3 indications and has 5 related U.S. FDA designations and 52 issued patents worldwide.
Longeveron (NASDAQ: LGVN) will report its 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, with dial-in 1.877.407.0789 and conference ID 13761959. An archived replay will be available on the Events & Presentations section of Longeveron’s website.
Longeveron (NASDAQ: LGVN) announced that Deborah D. Ascheim, M.D., a cardiologist and biotech executive with over 30 years of experience in gene, cell and biologic therapies, has been elected to its Board of Directors. According to Longeveron, she will help guide development of its stem cell therapy laromestrocel, including the hypoplastic left heart syndrome (HLHS) program, described as the company’s most advanced and near-term value catalyst.
Dr. Ascheim currently serves as Fractional Chief Medical Officer at Rejuvenate Bio and leads consulting firm d2a. Her prior roles include CMO positions at StrideBio and Capricor Therapeutics, and she has led or helped oversee NIH and industry-funded clinical trials totaling more than $140 million.
Longeveron (NASDAQ: LGVN) reported new post‑hoc analyses from its CLEAR-MIND Phase 2a trial of stem cell therapy laromestrocel in mild Alzheimer’s disease, presented at the 2026 Alzheimer’s Association International Conference (AAIC) in London.
According to Longeveron, free water MRI data suggested laromestrocel stabilized brain inflammation in key gray and white matter regions versus placebo, with trends toward reduced free water in structures such as the fornix, sagittal stratum, and uncinate fasciculus, and correlations with greater brain volume and improved cognitive and quality-of-life scores. Blood biomarker analyses showed reduced neurogranin levels and increased IL-13 versus placebo in certain dosing groups. Longeveron noted that laromestrocel holds FDA Regenerative Medicine Advanced Therapy and Fast Track designations for mild Alzheimer’s disease, and the company has aligned with the FDA on a Phase 3 study design.
Longeveron (NASDAQ: LGVN) appointed Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. She becomes principal financial and accounting officer, succeeding Lisa Locklear.
Washburn brings 20+ years of pharma/biotech finance experience. The company is focused on Phase 2b laromestrocel trial top-line results in HLHS, anticipated in the third quarter of 2026.
Longeveron (NASDAQ: LGVN)/b) announced that additional Phase 2a clinical data analysis of its stem cell therapy in mild Alzheimer’s disease was accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference (AAIC) in London, July 12-15, 2026.
The poster, titled “Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis,” will be presented Monday, July 13, 2026, 7:30am–4:15pm BST. According to Longeveron, prior CLEAR MIND Phase 2a results supporting laromestrocel’s therapeutic potential were published in Nature Medicine in March 2025.